1J. Grassinger,T. Südhoff,R. Andreesen,B. Hennemann. Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib[J] 2006,Annals of Hematology(2):132～133
2Orlowski RZ, Voorhees PM,Garcia RA,et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxoru bicin in patients with advanced hematologic malignancies [J].Blood, 2005,105 :3058-3065.
3Dai Y, Rahmani M, Pei XY,et al. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and-independent mechanisms [J ]. Blood, 2004,104: 509-518.
4Van de Stolpe A, Van der Saag PT. Intercellular adhesion moleculel[J]. J Mol Med,1996,74:13-33.
5Wissink S,van de Stolpe A,Caldenhoven E,et al. NF-kappa B/Rel family members regulating the ICAM-1 promoter in monocytic THP-1 cells [J]. Immunobiology, 1997,198:50-64.
6Jobin C,Hellerbrand C,Licato LL,et al. Mediation by NF-kappa B of cytokine induced expression of intercellular adhesion molecule 1 (ICAM-1) in an intestinal epithelial cell line,a process blocked by proteasome inhibitors[J]. Gut, 1998,42 : 779-787.
7Guzman ML,Neering SJ,Upchurch D,et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells [J].Blood, 2001,98:2301-2307.
8Yang L,Froio RM, Sciuto TE,et al. ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow[J]. Blood, 2005,106 : 584-592.
